Pulmatrix Inc., of Lexington, Mass., reported top-line data from a phase I pilot pharmacokinetic (PK) bioavailability trial of PUR0200, a dry powder formulation of a currently marketed once-daily bronchodilator, formulated using the company's Isperse technology, with results supporting continued development of the drug as a potential equivalent of the approved long-acting muscarinic antagonist for the maintenance of bronchospasm in patients with chronic obstructive pulmonary disease in Europe.